SIGA Shares Tumble as WHO Reports Decline in Global Monkeypox Cases -- Market Talk

Dow Jones2022-08-26

1506 ET - SIGA Technologies started working on its antiviral drug TPOXX nearly 20 years ago to help defend against a smallpox bioterrorism attack. But SIGA shares have more than doubled this year, driven by rising demand for TPOXX to treat monkeypox. But despite high interest from government health officials around the world, many countries are waiting to see if the epidemic continues to get worse before making large orders of the drug, SIGA CEO Phillip Gomez told Dow Jones in an interview. On Thursday, World Health Organization officials said at a press briefing that global monkeypox cases dropped 21% last week, and that there are signs of the epidemic slowing in Europe despite rising case counts in the US. SIGA shares are down 14%. (joseph.walker@wsj.com)

 

$(END)$ Dow Jones Newswires

August 25, 2022 15:06 ET (19:06 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment